{"filing":{"accession_number":"0001193125-26-266705","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"sln-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/sln-20260611.htm"},"events":[{"id":5335,"run_id":4673,"accession_number":"0001193125-26-266705","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6090,"accession_number":"0001193125-26-266705","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:36:07.075601+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6090,"accession_number":"0001193125-26-266705","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:36:07.075601+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-06-11"}]}